- Home
- EEA vs STRO Comparison
EEA vs STRO Comparison
Compare EEA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- STRO
- Stock Information
- Founded
- EEA 1986
- STRO 2003
- Country
- EEA Germany
- STRO United States
- Employees
- EEA N/A
- STRO N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EEA Finance
- STRO Health Care
- Exchange
- EEA Nasdaq
- STRO Nasdaq
- Market Cap
- EEA 57.7M
- STRO 50.0M
- IPO Year
- EEA N/A
- STRO 2018
- Fundamental
- Price
- EEA $9.66
- STRO $0.87
- Analyst Decision
- EEA
- STRO Hold
- Analyst Count
- EEA 0
- STRO 8
- Target Price
- EEA N/A
- STRO $6.14
- AVG Volume (30 Days)
- EEA 9.2K
- STRO 2.3M
- Earning Date
- EEA 01-01-0001
- STRO 05-08-2025
- Dividend Yield
- EEA 1.92%
- STRO N/A
- EPS Growth
- EEA N/A
- STRO N/A
- EPS
- EEA N/A
- STRO N/A
- Revenue
- EEA N/A
- STRO $66,434,000.00
- Revenue This Year
- EEA N/A
- STRO N/A
- Revenue Next Year
- EEA N/A
- STRO $1.29
- P/E Ratio
- EEA N/A
- STRO N/A
- Revenue Growth
- EEA N/A
- STRO N/A
- 52 Week Low
- EEA $7.45
- STRO $0.52
- 52 Week High
- EEA $9.26
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- EEA 66.34
- STRO 48.53
- Support Level
- EEA $9.53
- STRO $0.80
- Resistance Level
- EEA $9.87
- STRO $1.11
- Average True Range (ATR)
- EEA 0.15
- STRO 0.18
- MACD
- EEA 0.04
- STRO 0.02
- Stochastic Oscillator
- EEA 76.92
- STRO 41.53
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.